Literature DB >> 28604557

Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.

Cheol-Hwa Hong1, Hyun-Jung Sohn, Hyun-Joo Lee, Hyun-Il Cho, Tai-Gyu Kim.   

Abstract

Human leukocyte antigens (HLAs) are essential immune molecules that affect transplantation and adoptive immunotherapy. When hematopoietic stem cells or organs are transplanted with HLA-mismatched recipients, graft-versus-host disease or graft rejection can be induced by allogeneic immune responses. The function of each HLA allele has been studied using HLA-deficient cells generated from mutant cell lines or by RNA interference, zinc finger nuclease, and the CRISPR/Cas9 system. To improve HLA gene editing, we attempted to generate an HLA class I null cell line using the multiplex CRISPR/Cas9 system by targeting exons 2 and 3 of HLA-A, HLA-B, and HLA-C genes simultaneously. Multiplex HLA editing could induce the complete elimination of HLA class I genes by bi-allelic gene disruption on target sites which was defined by flow cytometry and target-specific polymerase chain reaction. Furthermore, artificial antigen-presenting cells were generated by transfer of a single HLA class I allele and co-stimulatory molecules into this novel HLA class I null cell line. Artificial antigen-presenting cells showed HLA-restricted antigen presentation following antigen processing and were successfully used for the efficient generation of tumor antigen-specific cytotoxic T cells in vitro. The efficient editing of HLA genes may provide a basis for universal cellular therapies and transplantation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28604557     DOI: 10.1097/CJI.0000000000000176

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  6 in total

Review 1.  CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

Authors:  Sasan Ghaffari; Nastaran Khalili; Nima Rezaei
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

2.  Identification of Naturally Processed Epitope Region Using Artificial APC Expressing a Single HLA Class I Allotype and mRNA of HCMV pp65 Antigen Fragments.

Authors:  Hong-Seon Pyo; Cheol-Hwa Hong; Haeyoun Choi; In-Cheol Baek; Tai-Gyu Kim
Journal:  Vaccines (Basel)       Date:  2022-05-16

3.  Generation of targeted homozygosity in the genome of human induced pluripotent stem cells.

Authors:  Yasuhide Yoshimura; Ayako Yamanishi; Tomo Kamitani; Jin-Soo Kim; Junji Takeda
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

4.  HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.

Authors:  Keven Hoerster; Markus Uhrberg; Constanze Wiek; Peter A Horn; Helmut Hanenberg; Stefan Heinrichs
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

5.  Extracellular vesicles from human umbilical cord blood plasma modulate interleukin-2 signaling of T cells to ameliorate experimental autoimmune encephalomyelitis.

Authors:  Sueon Kim; Ji-Young Maeng; Seung-Joo Hyun; Hyun-Jung Sohn; Su-Yeon Kim; Cheol-Hwa Hong; Tai-Gyu Kim
Journal:  Theranostics       Date:  2020-04-06       Impact factor: 11.556

6.  Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface.

Authors:  Yuki Okutani; Kengo Abe; Akihiro Yamashita; Miho Morioka; Shuichi Matsuda; Noriyuki Tsumaki
Journal:  Tissue Eng Part A       Date:  2021-08-20       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.